Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Sep 10 - Sep 15
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Hes not alone
Patients often combine BPC-157 with Sermorelin for enhanced healing and body composition support, NAD+ for cellular energy and recovery, or other targeted peptides based on their specific health goals
Additonal contributions: B
US$ 28.07
US$ 29.38
US$ 27.08
US$ 25.20
US$ 21.56
US$ 28.53
